Release Date: 2024-05-28

Epidemiology and Risk Factors in Bladder Cancer

Asif Yildirim (Author), Ayberk Iplikci (Author), Muhammed Kose (Author)

Release Date: 2024-05-28

In this section, we examined the epidemiology and risk factors of non-invasive bladder cancer. Bladder cancer is the 10th most commonly diagnosed cancer worldwide. Annual new diagnosis rates appear to be on the rise. Smoking was identified as the most significant modifiable risk factor. The non-modifiable risk factors were identified as age, race, genetics, and [...]

Media Type
  • PDF

Buy from

Price may vary by retailers

Work TypeBook Chapter
Published inCurrent Management of Non-Muscle Invasive Bladder Cancer
First Page1
Last Page13
DOIhttps://doi.org/10.69860/nobel.9786053359197.1
ISBN978-605-335-919-7 (PDF)
LanguageENG
Page Count13
Copyright HolderNobel Tıp Kitabevleri
Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing
In this section, we examined the epidemiology and risk factors of non-invasive bladder cancer. Bladder cancer is the 10th most commonly diagnosed cancer worldwide. Annual new diagnosis rates appear to be on the rise. Smoking was identified as the most significant modifiable risk factor. The non-modifiable risk factors were identified as age, race, genetics, and gender. Other risk factors discussed included environmental exposures, diet, occupational exposures, metabolic diseases, and urinary infections.

Asif Yildirim (Author)
Professor, Istanbul Medeniyet University
https://orcid.org/0000-0002-3386-971X
3Asif Yildirim received his Doctor of Medicine from the Marmara University School of Medicine and started the residency training in the Department of Urology at the same faculty in 1995. He completed his urological residency in 2000. He earned the degrees of Associate Professor in 2010, and Professor of Urology in 2016, and by February 2016 he joined the Department of Urology at Medical School of Medeniyet University. Dr. Yildirim specialized in the treatment of genitourinary cancers, including prostate cancer, bladder cancer, renal cancer and testicular cancer. His research interests include imaging, pathology and genetics of prostate cancer, bladder cancer and renal cancer.

Ayberk Iplikci (Author)
Istanbul Medeniyet University
https://orcid.org/0000-0002-5822-7799
3Ayberk Iplikci was born in Istanbul, Turkey. He obtained his medical degree from the Istanbul University, Istanbul Faculty of Medicine and completed his urology residency at the Istanbul Medeniyet University. In 2024, he successfully completed the written and oral examinations of the “European Board of Urology” and earned the title of “Fellow of European Board of Urology”. His areas of interest include uro-oncology, urolithiasis and andrology.

Muhammed Kose (Author)
Istanbul Medeniyet University
https://orcid.org/0000-0003-0475-9586
3Muhammed Kose works as a resident of urology in the Urology Department of Istanbul Medeniyet University. He participated in many congresses and scientific studies. He is particularly interested in the field of uro-oncology and urolithiasis.

  • 1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209–49.

  • 2. Compérat E, Larré S, Roupret M, Neuzillet Y, Pignot G, Quintens H, et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch. 2015 May;466(5):589–94.

  • 3. Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013 Feb;63(2):234–41.

  • 4. EAU Guidelines Office, Arnhem TN. EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). 2024;(ISBN: 978-94-92671-23-3).

  • 5. Teoh JY-C, Huang J, Ko WY-K, Lok V, Choi P, Ng C-F, et al. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. Eur Urol. 2020 Dec;78(6):893–906.

  • 6. Laaksonen MA, MacInnis RJ, Canfell K, Giles GG, Hull P, Shaw JE, et al. The future burden of kidney and bladder cancers preventable by behavior modification in Australia: A pooled cohort study. Int J cancer. 2020 Feb 1;146(3):874–83.

  • 7. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011 Aug 17;306(7):737–45.

  • 8. Kayyal-Tarabeia I, Blank M, Zick A, Agay-Shay K. Residence near industrial complex and cancer incidence: A registry-based cohort of 1,022,637 participants with a follow-up of 21 years, Israel. Environ Res. 2023 Jan 1;216(Pt 1):114471.

  • 9. Cumberbatch MG, Rota M, Catto JWF, La Vecchia C. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks. Eur Urol. 2016 Sep;70(3):458–66

  • 10. Koshiaris C, Aveyard P, Oke J, Ryan R, Szatkowski L, Stevens R, et al. Smoking cessation and survival in lung, upper aero-digestive tract and bladder cancer: cohort study. Br J Cancer. 2017 Oct 10;117(8):1224–32.

  • 11. Caini S, Del Riccio M, Vettori V, Francolini G, D’Ecclesiis O, Cai T, et al. Prognostic Impact of Post-Diagnosis Smoking Cessation among Bladder Cancer Patients: A Systematic Literature Review and Meta-Analysis. Cancers (Basel). 2022 Aug 20;14(16).

  • 12. Li Y, Tindle HA, Hendryx MS, Xun P, He K, Liang X, et al. Smoking Cessation and the Risk of Bladder Cancer among Postmenopausal Women. Cancer Prev Res (Phila). 2019 May;12(5):305–14.

  • 13. Al Hussein Al Awamlh B, Shoag JE, Ravikumar V, Posada L, Taylor BL, van der Mijn JC, et al. Association of Smoking and Death from Genitourinary Malignancies: Analysis of the National Longitudinal Mortality Study. J Urol. 2019 Dec;202(6):1248–54.

  • 14. Hinotsu S, Akaza H, Miki T, Fujimoto H, Shinohara N, Kikuchi E, et al. Bladder cancer develops 6 years earlier in current smokers: analysis of bladder cancer registry data collected by the cancer registration committee of the Japanese Urological Association. Int J Urol. 2009 Jan;16(1):64–9.

  • 15. Bjurlin MA, Matulewicz RS, Roberts TR, Dearing BA, Schatz D, Sherman S, et al. Carcinogen Biomarkers in the Urine of Electronic Cigarette Users and Implications for the Development of Bladder Cancer: A Systematic Review. Eur Urol Oncol. 2021 Oct;4(5):766–83.

  • 16. van Osch FH, Jochems SH, van Schooten F-J, Bryan RT, Zeegers MP. Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol. 2016 Jun;45(3):857–70.

  • 17. Zeegers MPA, Kellen E, Buntinx F, van den Brandt PA. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol. 2004 Feb 17;21(6):392–401.

  • 18. Yan H, Ying Y, Xie H, Li J, Wang X, He L, et al. Secondhand smoking increases bladder cancer risk in nonsmoking population: a meta-analysis. Cancer Manag Res. 2018 Sep;Volume 10:3781–91.

  • 19. Colt JS, Friesen MC, Stewart PA, Donguk P, Johnson A, Schwenn M, et al. A case-control study of occupational exposure to metalworking fluids and bladder cancer risk among men. Occup Environ Med. 2014 Oct;71(10):667–74.

  • 20. Pesch B, Taeger D, Johnen G, Gawrych K, Bonberg N, Schwentner C, et al. Screening for bladder cancer with urinary tumor markers in chemical workers with exposure to aromatic amines. Int Arch Occup Environ Health. 2014;87(7):715–24.

  • 21. Koutros S, Silverman DT, Baris D, Zahm SH, Morton LM, Colt JS, et al. Hair dye use and risk of bladder cancer in the New England bladder cancer study. Int J cancer. 2011 Dec 15;129(12):2894–904.

  • 22. Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, et al. Common germline-somatic variant interactions in advanced urothelial cancer. Nat Commun. 2020 Dec 3;11(1):6195.

  • 23. Mossanen M, Nassar AH, Stokes SM, Martinez-Chanza N, Kumar V, Nuzzo PV, et al. Incidence of Germline Variants in Familial Bladder Cancer and Among Patients With Cancer Predisposition Syndromes. Clin Genitourin Cancer. 2022 Dec;20(6):568–74.

  • 24. Egbers L, Grotenhuis AJ, Aben KK, Alfred Witjes J, Kiemeney LA, Vermeulen SH. The prognostic value of family history among patients with urinary bladder cancer. Int J cancer. 2015 Mar 1;136(5):1117–24.

  • 25. Murta-Nascimento C, Silverman DT, Kogevinas M, García-Closas M, Rothman N, Tardón A, et al. Risk of bladder cancer associated with family history of cancer: do low-penetrance polymorphisms account for the increase in risk? Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1595–600.

  • 26. García-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005 Aug;366(9486):649–59.

  • 27. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet. 2010 Nov 24;42(11):978–84.

  • 28. Riegert-Johnson DL, Gleeson FC, Roberts M, Tholen K, Youngborg L, Bullock M, et al. Cancer and Lhermitte-Duclos disease are common in Cowden syndrome patients. Hered Cancer Clin Pract. 2010 Dec 17;8(1):6.

  • 29. Casadei C, Dizman N, Schepisi G, Cursano MC, Basso U, Santini D, et al. Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors. Ther Adv Med Oncol. 2019;11:1758835919890285.

  • 30. Rossi M, Strikoudi P, Spei M-E, Parpinel M, Serraino D, Montella M, et al. Flavonoids and bladder cancer risk. Cancer Causes Control. 2019 May;30(5):527–35.

  • 31. Jochems SHJ, Reulen RC, van Osch FHM, Witlox WJA, Goossens ME, Brinkman M, et al. Fruit consumption and the risk of bladder cancer: A pooled analysis by the Bladder Cancer Epidemiology and Nutritional Determinants Study. Int J cancer. 2020 Oct 15;147(8):2091–100.

  • 32. Witlox WJA, van Osch FHM, Brinkman M, Jochems S, Goossens ME, Weiderpass E, et al. An inverse association between the Mediterranean diet and bladder cancer risk: a pooled analysis of 13 cohort studies. Eur J Nutr. 2020 Feb;59(1):287–96.

  • 33. Vieira AR, Vingeliene S, Chan DSM, Aune D, Abar L, Navarro Rosenblatt D, et al. Fruits, vegetables, and bladder cancer risk: a systematic review and meta-analysis. Cancer Med. 2015 Jan;4(1):136–46.

  • 34. Yu EYW, Wesselius A, Mehrkanoon S, Brinkman M, van den Brandt P, White E, et al. Grain and dietary fiber intake and bladder cancer risk: a pooled analysis of prospective cohort studies. Am J Clin Nutr. 2020 Nov 11;112(5):1252–66.

  • 35. Dianatinasab M, Wesselius A, Salehi-Abargouei A, Yu EYW, Fararouei M, Brinkman M, et al. Dietary fats and their sources in association with the risk of bladder cancer: A pooled analysis of 11 prospective cohort studies. Int J cancer. 2022 Jul 1;151(1):44–55.

  • 36. Dianatinasab M, Wesselius A, de Loeij T, Salehi-Abargouei A, Yu EYW, Fararouei M, et al. The association between meat and fish consumption and bladder cancer risk: a pooled analysis of 11 cohort studies. Eur J Epidemiol. 2021 Aug;36(8):781– 92.

  • 37. Al-Zalabani AH, Stewart KFJ, Wesselius A, Schols AMWJ, Zeegers MP. Modifiable risk factors for the prevention of bladder cancer: a systematic review of meta-analyses. Eur J Epidemiol. 2016 Sep;31(9):811–51.

  • 38. Lotan Y, Goodman PJ, Youssef RF, Svatek RS, Shariat SF, Tangen CM, et al. Evaluation of vitamin E and selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. J Urol. 2012 Jun;187(6):2005–10.

  • 39. Pelucchi C, Galeone C, Tramacere I, Bagnardi V, Negri E, Islami F, et al. Alcohol drinking and bladder cancer risk: a meta-analysis. Ann Oncol Off J Eur Soc Med Oncol. 2012 Jun;23(6):1586–93.

  • 40. Steinmaus C, Ferreccio C, Acevedo J, Yuan Y, Liaw J, Durán V, et al. Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure. Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1529–38.

  • 41. Koutros S, Baris D, Waddell R, Beane Freeman LE, Colt JS, Schwenn M, et al. Potential effect modifiers of the arsenic-bladder cancer risk relationship. Int J cancer. 2018 Dec 1;143(11):2640–6.

  • 42. Zhang Y, Birmann BM, Han J, Giovannucci EL, Speizer FE, Stampfer MJ, et al. Personal use of permanent hair dyes and cancer risk and mortality in US women: prospective cohort study. BMJ. 2020 Sep 2;370:m2942.

  • 43. Moschini M, Zaffuto E, Karakiewicz PI, Andrea DD, Foerster B, Abufaraj M, et al. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. Eur Urol. 2019 Feb;75(2):319–28.

  • 44. Minami T, Fujita K, Hashimoto M, Nishimoto M, Adomi S, Banno E, et al. External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy. World J Urol. 2023 May;41(5):1317–21.

  • 45. Chrouser K, Leibovich B, Bergstralh E, Zincke H, Blute M. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol. 2005 Jul;174(1):107–10; discussion 110-1.

  • 46. Zelefsky MJ, Housman DM, Pei X, Alicikus Z, Magsanoc JM, Dauer LT, et al. Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):953–9.

  • 47. Teleka S, Häggström C, Nagel G, Bjørge T, Manjer J, Ulmer H, et al. Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: A prospective pooled cohort study of 800,000 men and women. Int J cancer. 2018 Dec 15;143(12):3071–82.

  • 48. Qin Q, Xu X, Wang X, Zheng X-Y. Obesity and risk of bladder cancer: a meta-analysis of cohort studies. Asian Pac J Cancer Prev. 2013;14(5):3117–21.

  • 49. Keimling M, Behrens G, Schmid D, Jochem C, Leitzmann MF. The association between physical activity and bladder cancer: systematic review and meta-analysis. Br J Cancer. 2014 Apr 2;110(7):1862–70.

  • 50. Tuccori M, Filion KB, Yin H, Yu OH, Platt RW, Azoulay L. Pioglitazone use and risk of bladder cancer: population based cohort study. BMJ. 2016 Mar 30;352:i1541.

  • 51. Adil M, Khan RA, Ghosh P, Venkata SK, Kandhare AD, Sharma M. Pioglitazone and risk of bladder cancer in type 2 diabetes mellitus patients: A systematic literature review and meta-analysis of observational studies using real-world data. Clin Epidemiol Glob Heal. 2018 Jun;6(2):61–8.

  • 52. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog risks to humans. 1994;61:1–241.

  • 53. Inobaya MT, Olveda RM, Chau TN, Olveda DU, Ross AG. Prevention and control of schistosomiasis: a current perspective. Res Rep Trop Med. 2014 Oct 17;2014(5):65–75.

  • 54. Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C. Mechanisms of disease: The epidemiology of bladder cancer. Nat Clin Pract Urol. 2006 Jun;3(6):327–40.

  • 55. Bayne CE, Farah D, Herbst KW, Hsieh MH. Role of urinary tract infection in bladder cancer: a systematic review and meta-analysis. World J Urol. 2018 Aug;36(8):1181–90.

  • 56. Yu Z, Yue W, Jiuzhi L, Youtao J, Guofei Z, Wenbin G. The risk of bladder cancer in patients with urinary calculi: a meta-analysis. Urolithiasis. 2018 Nov;46(6):573–9.

  • 57. Chappidi MR, Kates M, Tosoian JJ, Johnson MH, Hahn NM, Bivalacqua TJ, et al. Evaluation of gender-based disparities in time from initial haematuria presentation to upper tract urothelial carcinoma diagnosis: analysis of a nationwide insurance claims database. BJU Int. 2017 Sep;120(3):377–86.

  • 58. Liu S, Yang T, Na R, Hu M, Zhang L, Fu Y, et al. The impact of female gender on bladder cancer-specific death risk after radical cystectomy: a meta-analysis of 27,912 patients. Int Urol Nephrol. 2015 Jun;47(6):951–8.

  • 59. Cohn JA, Vekhter B, Lyttle C, Steinberg GD, Large MC. Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claimsbased investigation. Cancer. 2014 Feb 15;120(4):555–61.

  • 60. Dietrich K, Demidenko E, Schned A, Zens MS, Heaney J, Karagas MR. Parity, early menopause and the incidence of bladder cancer in women: a case-control study and meta-analysis. Eur J Cancer. 2011 Mar;47(4):592–9.

  • 61. Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer. 2009 Jan 1;115(1):68–74.

  • 62. Abufaraj M, Shariat S, Moschini M, Rohrer F, Papantoniou K, Devore E, et al. The impact of hormones and reproductive factors on the risk of bladder cancer in women: results from the Nurses’ Health Study and Nurses’ Health Study II. Int J Epidemiol. 2020 Apr 1;49(2):599–607.

  • 63. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan;70(1):7–30.

  • 64. Shariat SF, Milowsky M, Droller MJ. Bladder cancer in the elderly. Urol Oncol. 2009;27(6):653–67.

  • 65. Yee DS, Ishill NM, Lowrance WT, Herr HW, Elkin EB. Ethnic differences in bladder cancer survival. Urology. 2011 Sep;78(3):544–9.

  • 66. Lane G, Risk M, Fan Y, Krishna S, Konety B. Persistent muscle-invasive bladder cancer after neoadjuvant chemotherapy: an analysis of Surveillance, Epidemiology and End Results-Medicare data. BJU Int. 2019 May;123(5):818–25.

Share This Chapter!